

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4502730
<b>Application Number:</b>	10581656
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3937
<b>Title of Invention:</b>	Oligonucleotides Derived From Mycobacterium for Stimulating Immune Function, Treating Immune-Related Diseases, Atopic Dermatitis and/or Protecting Normal Immune Cell
<b>First Named Inventor/Applicant Name:</b>	Hyung-Joo Kwon
<b>Customer Number:</b>	72960
<b>Filer:</b>	Tanya A Arenson/Jasmine Stansberry
<b>Filer Authorized By:</b>	Tanya A Arenson
<b>Attorney Docket Number:</b>	BARUN-10974
<b>Receipt Date:</b>	22-DEC-2008
<b>Filing Date:</b>	09-JUN-2008
<b>Time Stamp:</b>	16:36:16
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2799
Deposit Account	504302
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		RRR_10974.pdf	103536	yes	5
			82eaba41a24d5d5b85179fe29a82a0bc9f49c210		
	Multipart Description/PDF files in .zip description				
	Document Description		Start		End
	Amendment/Req. Reconsideration-After Non-Final Reject		1		1
	Claims		2		3
	Applicant Arguments/Remarks Made in an Amendment		4		5
Warnings:					
Information:					
2	Information Disclosure Statement Letter	IDSletter.pdf	75580	no	2
			f00d2d62c0d4a1e694a58621eb0bc7330345ff19		
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed (SB/08)	SB08.pdf	609609	no	5
			bd8f88b10f193215724d80c97b79d91ce74625e3		
Warnings:					
Information:					
4	NPL Documents	KLINMAN1996PNASVol93pp2879-83.pdf	1093373	no	5
			43f741c1b874842172487e603b335559fd7f676e		
Warnings:					
Information:					
5	NPL Documents	AKDIS2000CurrOpinImmunolVol12pp641-6.pdf	1574294	no	9
			d1d2a670d3f452f853251a05b658ea6e3547dc39		
Warnings:					
Information:					
6	NPL Documents	KWON2003BiochemBiophysResVol311pp129-38.pdf	1831873	no	13
			4b680abe69fe407b3d54b95a0cb17d7cd82f1c63		
Warnings:					

Information:					
7	NPL Documents	PROSSER1976IntJRadiateBioVol l30pp459-65.pdf	700484	no	10
			b479380d0d6c4ca1e87837419d7c5307f33de07		
Warnings:					
Information:					
8	NPL Documents	ASHWELL1986JImmunolVol136 pp3649-56.pdf	1737143	no	11
			b52f8d5c3b88577fb29620e5f80a97f7b08a83a9		
Warnings:					
Information:					
9	NPL Documents	IMOKAWA1991JInvestDermatol Vol96pp523-6.pdf	936494	no	7
			a04a3cee440b572c3e36809e015c8a0e0f70b906		
Warnings:					
Information:					
10	NPL Documents	RUDIHOFF1998LancetVol351pp 1717.pdf	1639437	no	9
			150ab180ad66e5efae20c0067170c6517d6c7d31		
Warnings:					
Information:					
11	NPL Documents	KRIEG2005NatureVol374pp546 -9-fromAUCase.pdf	1057559	no	4
			c55b1fe82a9d138a79fba03ada0b5e1445d3c7fc		
Warnings:					
Information:					
12	NPL Documents	KRIEG2002AnnuRevImmunolV ol20pp709-60-fromAU-CNcase. pdf	5028400	no	34
			6048145bff204c932cafd86b729626570cdb7c3a		
Warnings:					
Information:					
13	NPL Documents	UHLMANN2003CurrOpinDrugD iscDevVol6pp204-17- FromEPcase.pdf	2744091	no	14
			18ebc98c2e4e1ad4d3d1843245541b471bd4b460		
Warnings:					
Information:					
14	NPL Documents	KRIEG-Univlowapp1-22- fromEPcase.pdf	2479860	no	22
			1298fe113481e74560ecf1837e65026112a183f2		
Warnings:					
Information:					
15	Foreign Reference	WO199840100-FromEPcase.pdf	2746432	no	69
			97be3761e1139a19a8b89e34fd50534ab81da0c7		
Warnings:					

Information:					
16	NPL Documents	DAVIS1998JImmunolVol160pp870-6.pdf	164105	no	7
			520df558ee349984fc351b1f8f11438aeb179d2		
Warnings:					
Information:					
17	NPL Documents	TANAKA1992Vol175pp597-607.pdf	1345093	no	11
			9c4a977193bef59c26bfa211b8a1628c8ffee405		
Warnings:					
Information:					
18	NPL Documents	DENG2000ArthritisRheumatismVol43pp356-64.pdf	937965	no	9
			e97e92d039f1f976e72bd77b63e78fc8ee4b137a		
Warnings:					
Information:					
19	NPL Documents	BALLAS1996JImmunolVol157pp1840-5-1.pdf	574316	no	6
			1d98c2e1d83bae34d5ec296ae23ad168721b2fe3		
Warnings:					
Information:					
20	NPL Documents	KUBOTA2004JRadiatResVol45pp205-11SCANNED.pdf	564459	no	7
			ca2cfc0dbee41bbafc2125e24c367db75a2a9b35		
Warnings:					
Information:					
21	Fee Worksheet (PTO-06)	fee-info.pdf	30649	no	2
			e1da4a1bb1e012036e06eae205fc938268993285		
Warnings:					
Information:					
Total Files Size (in bytes):			27974752		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**